News
Press ReleaseRevive Therapeutics Announces Results of Annual Shareholder Meeting
Revive Therapeutics is pleased to announce the voting results for its annual and special meeting of shareholders (the “Meeting”) that was held on Tuesday, March 18, 2025.
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
Revive Therapeutics shares an update on R&D efforts, focusing on Bucillamine for infectious diseases and medical countermeasures. Learn more about their progress.
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
Revive Therapeutics shares an update on R&D efforts, focusing on Bucillamine for infectious diseases and medical countermeasures. Learn more about their progress.
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics updates on its research evaluating Bucillamine for nerve agent exposure, showcasing advancements in innovative therapeutic solutions
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
Revive Therapeutics Ltd. updates on study with Defence R&D Canada to explore Bucillamine as a potential treatment for nerve agent exposure-induced brain injury.
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics Ltd. updates on study with Defence R&D Canada to explore Bucillamine as a potential treatment for nerve agent exposure-induced brain injury.